Detection of
H
istoplasma capsulatum is endemic to the Midwest United States, particularly along the Mississippi River and Ohio River valleys, and currently is the most common dimorphic fungal infection among individuals Ն65 years of age (1, 2). The clinical manifestations of H. capsulatum infection are largely dependent on the fungal burden at the time of exposure and the patient's underlying immune status. While the vast majority (Ͼ90%) of exposed individuals remain asymptomatic, those seeking medical attention can present with symptoms ranging from a self-limited pulmonary illness to severe disseminated disease (3) . Hematogenous dissemination most commonly occurs in individuals who are at the extremes of age or have impaired cellular immunity, including patients with AIDS, patients who have undergone recent organ transplantation, and patients with hematological malignancies (4, 5) . For these patients, rapid accurate diagnosis and prompt initiation of antifungal therapy are critical for disease management and positive outcomes.
The available laboratory methods for the diagnosis of H. capsulatum infections include culture, histopathological evaluation, molecular techniques (e.g., real-time PCR), serological testing, and antigen detection. The clinical sensitivity and specificity of each of these methods are dependent on the patient's immune status, disease manifestation, and duration of symptoms prior to presentation. While culture remains the "gold standard" diagnostic test and is highly specific, H. capsulatum may require prolonged incubation (2 to 4 weeks), which may delay the initiation of antifungal therapy. In addition, the sensitivity of fungal culture can be low (9 to 34%) in cases of acute or localized disease (3, 6) . Histopathological evaluation lacks sensitivity and requires invasive procedures that may be contraindicated for high-risk patient populations (7, 8) . Molecular assays (e.g., real-time PCR) for the detection of H. capsulatum from respiratory and tissue specimens are rapid and highly specific; however, the sensitivity of real-time PCR was recently reported to be 73% (11/15 cases) overall, compared to culture, and only 33% (2/6 cases) for bronchoalveolar lavage (BAL) fluid (9) . Serological detection of antibodies to H. capsulatum using complement fixation and immunodiffusion is highly specific, but results may be falsely negative for immunosuppressed patients or individuals who present with recent infection (3, 8) . Also, antibodies may persist for years following disease resolution, thereby limiting the clinical specificity of serological testing in some cases.
Due to the limitations of routine laboratory methods, detection of Histoplasma antigen in urine and serum specimens has become a fundamental tool for the diagnosis of histoplasmosis. Numerous studies have reported on the increased sensitivity of the MiraVista (MVista) Histoplasma urinary antigen (UAg) assay (MiraVista Diagnostics, Indianapolis, IN) in comparison with conventional methods for the detection of histoplasmosis, particularly during acute (75 to 80%) and disseminated (Ͼ90%) disease, in both immunosuppressed patients and otherwise healthy individuals (3, 8, 10) . These findings have led many health care providers to rely heavily on this assay as an indicator of active disease. Furthermore, as both urine and serum Histoplasma antigen levels generally decrease following the initiation of treatment, quantitative Histoplasma antigen values are routinely monitored as indicators of responses to antifungal therapy (11, 12) . Despite the clinical utility of antigen detection, the MVista Histoplasma UAg assay has a number of limitations, including cross-reactivity with other fungi (i.e., Blastomyces dermatitidis, Coccidioides species, Sporothrix schenckii, Paracoccidioides brasiliensis, and Penicillium marneffei) (13, 14) . In addition, the MVista assay is not commercially available, which prevents clinical laboratories from performing the test in-house to provide the fastest turnaround. This potential delay in turnaround is a concern, as prompt initiation of antifungal therapy, particularly for patients with acute pulmonary or disseminated histoplasmosis, is associated with improved patient outcomes (2) . Finally, the reportable range of the MVista assay is currently Ն0.4 to 19 ng/ml, and results of Ͼ0 to Ͻ0.4 ng/ml are reported as "positive, below the limit of quantification." The clinical significance of these low positive results, however, has not been defined.
Currently (This study was presented in part at the 113th General Meeting of the American Society for Microbiology, Denver, CO, 2013 [16] .)
MATERIALS AND METHODS
Study design. Urine samples (n ϭ 1,003) submitted to our reference laboratory for detection of Histoplasma capsulatum antigen were forwarded to MiraVista Diagnostics (Indianapolis, IN) for testing by the MVista Histoplasma capsulatum antigen EIA. Prior to forwarding to MiraVista, a minimum of 1 ml of each urine sample was obtained for analysis in our laboratory. Urine samples were tested in a blinded fashion for Histoplasma UAg, using an analyte-specific reagent (ASR) EIA (Immuno Mycologics, Inc.
[IMMY], Norman, OK) targeting H. capsulatum galactomannan (GM). Qualitative results obtained with the IMMY ASR EIA and the MVista EIA were compared, and samples with discordant results following initial testing underwent repeat testing with both assays. For samples with discrepant results after repeat testing, the ordering providers were contacted to determine the final patient diagnosis. In addition to the prospective study, 11 stored urine samples collected from patients with culture-proven histoplasmosis were tested by the IMMY ASR and MVista EIAs. This study was approved by the institutional review board of the Mayo Clinic.
MVista H. capsulatum urinary antigen EIA. All urine samples (n ϭ 1,003) included in this study were submitted for clinical testing with the MVista H. capsulatum antigen assay, which is a quantitative noncompetitive antigen-capture EIA. Results are reported as positive or negative, with a quantitative range of 0.4 to 19 ng/ml. Samples with results of Ͼ0 to Ͻ0.4 ng/ml and Ͼ19 ng/ml are reported as "positive, below the limit of quantification," and "positive, above the limit of quantification," respectively.
IMMY H. capsulatum GM ASR EIA. The IMMY ASR EIA is a quantitative, antigen-capture immunoassay for detection of H. capsulatum GM antigen in urine and was performed on a Triturus automated EIA analyzer (Grifols, Miami, FL). Undiluted urine (0.1 ml) was added directly to microtiter wells coated with monoclonal antibody specific for H. capsulatum GM. Following incubation and washing, horseradish peroxidase (HRP)-conjugated anti-GM monoclonal antibody was added and incubated. Excess conjugate was removed, and remaining, bound, HRP-conjugated antibody was detected with the addition of 3,3=,5,5=-tetramethylbenzidine (TMB). The optical density (OD) of the reaction mixture was measured by the Triturus instrument at dual excitation wavelengths of 450/620 nm. OD results were compared to a standard curve generated with seven calibrator solutions (calibrator concentrations of 0.4, 0.8, 1.6, 3.2, 6.3, 12.5, and 25 ng/ml) to determine the quantitative value and the associated qualitative interpretation. According to the manufacturer, the linearity of this assay ranges from 0.4 ng/ml to 25 ng/ml, and values of Ͼ0.5 ng/ml were considered positive.
Resolution of discordant results. Samples with discordant qualitative results were retested with both assays. For samples with discordant results following repeat testing, providers were contacted to determine the clinical diagnosis and treatment decisions for the patient. Parameters that were recorded included (i) reason for H. capsulatum UAg testing, (ii) relevant laboratory findings (i.e., fungal culture results and fungal serological testing results), (iii) treatment, and (iv) final clinical diagnosis.
Statistical analysis. Overall percent agreement, kappa values, and 95% confidence intervals (CIs) were determined using GraphPad software for qualitative (positive/negative) results from the IMMY ASR EIA in comparison with the MVista EIA, which was considered the reference standard for this study. Receiver operating characteristic (ROC) curve analysis was performed to identify the optimal cutoff value for the IMMY ASR assay. For samples reported as Ͻ0.4 ng/ml by the IMMY assay, an additional 0 ng/ml calibrator (a theoretical dilution from the lowest calibrator concentration to 0 ng/ml) was included in the calibration curve and the results were reanalyzed to determine the absolute numerical value for ROC analysis. The area under the ROC curve (AUC) was calculated using the method described by Hanley and McNeil (17) . A test with an AUC of 0.9 or higher is considered an outstanding test (18) . The optimal cutoff value based on the ROC curve was determined such that the total sensitivity and specificity were maximized.
RESULTS
Following testing of 1,003 prospectively collected urine samples, the IMMY ASR assay showed overall percent agreement with the MVista EIA of 97.6% (979/1,003 samples) ( Table 1 ). The associated value was 0.75, which indicates substantial agreement between the two methods. Compared to the MVista EIA, the IMMY ASR EIA showed high specificity (99.8% [939/941 samples]); however, the sensitivity was low (64.5% [40/62 samples]). Quantitative values did not correlate between the two EIAs, and values from the IMMY ASR assay were consistently lower than those from the MVista EIA (see Table S1 in the supplemental material). During our initial analysis, the qualitative interpretation of the IMMY ASR assay results was based on the manufacturer's recommended cutoff value of Ͼ0.5 ng/ml (positive). We then performed a ROC analysis to determine if an alternative cutoff value would enhance the performance of the IMMY ASR assay. This analysis identified a positive cutoff value of Ͼ0.15 ng/ml, at which both sensitivity and specificity were maximized. Using this newly defined cutoff value, the sensitivity of the IMMY ASR EIA improved to 80.7% (50/62 samples); however, the overall percent agreement and specificity decreased to 95.3% (956/1,003 samples) and 96.3% (906/941 samples), respectively. The ROC AUC was 0.901 (outstanding test performance) (Fig. 1) . In addition to the prospective study, 11 urine samples collected from patients with culture-proven histoplasmosis (specimen sources for cultures included BAL fluid, blood, bone, synovial fluid, bone marrow, and lymphoid tissue) were tested by the IMMY ASR EIA and all 11 samples were positive, with quantitative values ranging from 0.51 ng/ml to Ͼ25 ng/ml (median, 4.8 ng/ml). Of these 11 specimens, 10 had been tested by the MVista EIA and all 10 results were reported as positive. Similar to the prospective data, the quantitative values of the IMMY ASR and MVista EIAs did not show a high degree of correlation (see Table  S2 in the supplemental material).
DISCUSSION
This study is the first to assess the performance of the IMMY H. capsulatum GM EIA, a commercially available assay for the detection of H. capsulatum antigen in urine. Using prospectively collected urine specimens (n ϭ 1,003 Although our data suggest that the IMMY ASR EIA is less sensitive than the MVista EIA, the results should be interpreted with a certain level of caution. First, accurate definitive diagnosis of histoplasmosis requires collective interpretation of the results of a battery of tests, including fungal culture, serological testing, antigen detection, and histopathological evaluation, if available. Therefore, establishing the MVista EIA as the sole reference standard for the prospective portion of our study is a limitation that should be emphasized. Due to this limitation, we performed a thorough analysis of the samples showing discordant results between the MVista and IMMY EIAs (Fig. 2) . Among the 1,003 prospective samples tested in our study, 24 (2.4%) showed discordant results. In resolving these discrepancies, the ordering providers for 23 of the 24 patients were able to be reached to obtain pertinent information, such as patient history, other laboratory findings, treatment decisions, and final diagnosis ( Table 2 ). The MVista EIA was ordered as a component of the initial diagnostic workup for nine of those 23 patients, and five showed MVista EIA results considered by the ordering provider to be falsely positive (Table 2 , patients 4, 14, 20, 21, and 22). Among these five patients, one was ultimately diagnosed with infection with B. dermatitidis, an organism known to produce false-positive MVista Histoplasma UAg results, one patient died as a result of influenza-related pneumonia, and three patients had negative Histoplasma culture and serological test results and did not receive antifungal treatment. The MVista EIA quantitative values for three of these five patients were Ͻ0.4 ng/ml (below the limit of quantification). Two of the nine samples submitted for initial diagnostic testing ( Table 2 , patients 9 and 18) were IMMY assay positive and MVista assay negative; based on provider information, the results were considered to be falsely positive by the IMMY ASR assay. One of these 2 patients was ultimately diagnosed with Coxiella burnetii endocarditis, and all Histoplasma culture and serological test results remained negative for the second patient.
The remaining 14 discordant specimens (all MVista positive and IMMY negative) were collected to monitor Histoplasma UAg tive results of the IMMY GM EIA were compared with those of the MVista EIA, which was established as the reference standard. The area under the ROC curve (AUC) was calculated using the method described by Hanley and McNeil (17) . A test with an AUC of 0.9 or higher is considered an outstanding test (18) . The optimal cutoff value based on the ROC curve was determined such that the total sensitivity and specificity were maximized. levels after a diagnosis of histoplasmosis had been made and therapy initiated. Among these 14 patients, 8 ( Table 2 , patients 1, 2, 3, 6, 10, 13, 19, and 24) had been diagnosed with histoplasmosis at least 1 year earlier and 5 patients continued to receive antifungal therapy. In addition, six of the 14 patients had MVista EIA quantitative values of Ͻ0.4 ng/ml (below the limit of quantification) and two patients had quantitative values of 0.51 ng/ml (the reportable range of the MVista EIA changed from 0.6 to 39 ng/ml to 0.4 to 19 ng/ml in 2012).
The clinical significance of a positive but not quantifiable (Ͻ0.4 ng/ml) MVista EIA result has not been studied in detail, and the proper interpretation of this finding is not clear. Interestingly, a separate retrospective review of patients (n ϭ 26) seen at our institution who had not been previously diagnosed with Histoplasma infection but had positive MVista UAg EIA results (Ͻ0.6 ng/ml) showed that 46.1% (12/26 cases) were considered to be falsely positive by the ordering provider (E. S. Theel, unpublished data). These data suggest that low positive MVista UAg EIA results should be interpreted with caution; however, further prospective studies are needed to better characterize the significance of these results.
It is well documented that, for patients who have been previously diagnosed with histoplasmosis, serial monitoring of Histoplasma antigen levels can be used to monitor the response to therapy, whereby significant decreases in antigen levels are commonly associated with favorable outcomes while consistently elevated or increasing antigen levels may suggest treatment failure (3, 19) . Also, some patients who are clinically improving may continue to In addition to our prospective study, we were able to evaluate the performance of the IMMY ASR EIA using 11 urine samples collected from patients with culture-confirmed histoplasmosis. We observed excellent correlation between the IMMY and MVista EIA results for these previously undiagnosed/untreated patients. The IMMY GM EIA results were positive in all 11 (100%) of these cases, and the MVista assay results also were positive for 100% (10/10 samples) of the samples tested. Despite these promising results, additional prospective studies in which the IMMY ASR and MVista assays are compared using a comprehensive reference standard (fungal culture, serological, histopathological, and radiological findings and treatment decisions) will be needed.
In summary, we have demonstrated that the IMMY Histoplasma GM ASR assay shows excellent overall agreement (97.6%; ϭ 0.75) and specificity (99.8%) but low sensitivity (64.5%), compared with the MVista UAg EIA. Closer evaluation of the discrepant cases revealed that 45.5% (10/22 samples) of the IMMY assay-negative/MVista assay-positive samples were below the current limit of quantification for the MVista assay. The clinical significance of these results, particularly for patients receiving antifungal therapy for a prior diagnosis of histoplasmosis, is unclear. While our findings suggest that the IMMY ASR assay may represent an alternative method to detect Histoplasma UAg, additional evaluation of this assay is needed to better characterize its clinical sensitivity in untreated patients, the kinetics of antigen clearance as measured by this test, and the ability of antigen tests in general to predict treatment success or failure.
